Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy(ADT)for High Risk Prostate Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Proxalutamide combined with androgen deprivation therapy(ADT)for High risk prostate cancer ,This trial is A randomized, controlled, double-blind, single center.Treatment cycle is 6 months,
Epistemonikos ID: 3cf59ba59c60e9d5130766e04dfe05d48bcfa8b1
First added on: May 09, 2024